Roche launches genomic profiling kit to ease cancer research

ZURICH, (Reuters) - Roche (ROG.S) is launching a new genomic profiling kit that lets cancer researchers explore tumours without having to send tissue samples to centralised laboratories, the Swiss drugmaker said on Monday.

The AVENIO Tumour Tissue Comprehensive Genomic Profiling (CGP) Kit was developed with Roche unit Foundation Medicine, a molecular information specialist whose products help doctors match patients to appropriate therapies and clinical trials.

"The Kit complements the current CGP portfolio offered by Roche and Foundation Medicine and allows laboratories to expand their oncology research in-house," Roche said in a statement, giving no financial information about the product.

"Ultimately, a future version of the kit may lead to additional resources for clinicians to use in the diagnosis and treatment of cancer."



Popular posts from this blog

EMA Recommends Extension of Indications for Ramucirumab

Dr. Hootie Warren takes helm of Fred Hutch Global Oncology

Bristol-Myers Squibb and Clovis Oncology Announce a Broad Clinical Collaboration to Evaluate Combination of Opdivo (Nivolumab) and Rubraca® (Rucaparib) in Phase 2 and Pivotal Phase 3 Clinical Trials in Multiple Tumor Types